10th Dec 2018 09:06
LONDON (Alliance News) - ValiRx PLC on Monday said an independent analysis of VAL201 showed a positive effect on patients with hormone-sensitive and hormone-resistant prostate cancer.
The stock was up by 38% at 1.65 pence a share on Monday.
The study was undertaken using a non-parametric approach - both the well-established Friedman test and the most up-to-date statistical method, repeated measures multiple correlation analysis.
This analysis revealed that volunteers treated with VAL201 displayed a "statistically significant" correlation for reductions over time in the amount of testosterone and prostate specific antigen, which stimulate the progression of prostate cancer.
"I am delighted to receive this analysis from an external expert, showing that VAL201 is having a positive and desired effect on prostate cancer patients' disease markers," said ValiRx Chief Executive Satu Vainikka.
"Effectively, the more a patient takes VAL201, the more a patient's prostate specific antigen will decrease," added Vainikka.
Related Shares:
ValiRx